FibroNox is focused on developing patented first-in-class therapeutics to treat and reverse life-threatening fibrotic diseases. FibroNox has pioneered the development of selective Nox4 inhibitors and Nrf2 activators that have shown robust protection from fibrosis development and promoted the reversal of age-associated established fibrosis. FibroNox’s initial focus is treating idiopathic pulmonary fibrosis and fibrosis in Duchenne muscular dystrophy. FibroNox’s therapeutics offer the opportunity to reverse age-associated established fibrosis, representing the holy grail for more effective strategies to treat fibrotic diseases.

FibroNox, Inc.

Joseph Patti

This department oversees the strategic direction and operational management of the organization.

FibroNox, Inc.

Org chart

Teams

Executive Leadership

Offices

FibroNox, Inc.

Org chart

Teams

Executive Leadership

Offices

Related companies